BEACOPP

from Wikipedia, the free encyclopedia

The BEACOPP scheme is a cytostatic therapy that was developed by the German Hodgkin study group . The BEACOPP scheme is chemotherapy with the following drugs in the following dosage:

BEACOPP basis in the order of administration: (mg / m² = amount / body surface area)

C yclophosphamid 650 mg / m² iv day 1
E toposid (phosphate) 100 mg / m² iv Day 1-3
A driamycin 25 mg / m² iv day 1
P rocarbazine 100 mg / m² po Day 1-7
Vincristine (= O ncovin ® ) 1.4 mg / m² (max. 2 mg) iv Day 8
B leomycin 10 mg / m² iv Day 8
P redniso (lo) n 40 mg / m² po Day 1-14

BEACOPP escalates:

Cyclophosphamide  1200 mg / m² KO / day  iv day 1
Etoposide (phosphate) 200 mg / m² iv Day 1-3
Adriamycin 35 mg / m² iv day 1
Procarbazine 100 mg / m² po Day 1-7
Vincristine 1.4 mg / m² (max. 2 mg) iv Day 8
Bleomycin 10 mg / m² iv Day 8
Predniso (lo) n 40 mg / m² po Day 1-14

The duration of a cycle is 21 days. Days 15–21 are used for relaxation. No medication is administered here. The cycle duration can also be 14 days, in which case there is no recovery phase. Usually eight, sometimes six cycles are performed. If medically indicated, the intravenous administration of medication on day 8 can be omitted. This usually happens in the later cycles.

Therapy usually takes place on an outpatient basis.

In the therapy of advanced Hodgkin lymphoma, the balance between effectiveness and tolerability, i.e. the reduction of side effects while maintaining the same level of therapeutic success, is an essential goal. For this purpose, the GHSG is conducting the "Targeted BEACOPP" study (NCT01569204): The two chemotherapeutic agents Vincristine and bleomycin are replaced by the antibody-drug conjugate brentuximab vedotin, with the aim of improving the effectiveness with reduced toxicity. An interim evaluation gave no indications of increased toxicity or decreased effectiveness.

indication

The BEACOPP scheme is used in advanced Hodgkin's disease .

Individual evidence

  1. ↑ http://www.ghsg.org/ghsg
  2. ↑ Volker Diehl, Jeremy Franklin, Michael Pfreundschuh, Bernd Lathan, Ursula Paulus: Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease . In: New England Journal of Medicine . tape 348 , no. 24 , p. 2386-2395 , doi : 10.1056 / nejmoa022473 ( nejm.org [PDF]).
  3. ↑ P. Borchmann et al .: Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study. In: Blood 2013; 122: 4344.

See also